Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults.
Riste M, Marshall JL, Satti I, Harris SA, Wilkie M, Lopez Ramon R, Wright D, Wittenberg RE, Vermaak S, Powell Doherty R, Lawrie A, Conlon CP, Cosgrove C, Gleeson F, Lipman M, Moss P, Perrin F, Dedicoat M, Bettinson H, McShane H. Riste M, et al. Among authors: vermaak s. Vaccines (Basel). 2021 Apr 16;9(4):396. doi: 10.3390/vaccines9040396. Vaccines (Basel). 2021. PMID: 33923628 Free PMC article.
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
Manjaly Thomas ZR, Satti I, Marshall JL, Harris SA, Lopez Ramon R, Hamidi A, Minhinnick A, Riste M, Stockdale L, Lawrie AM, Vermaak S, Wilkie M, Bettinson H, McShane H. Manjaly Thomas ZR, et al. Among authors: vermaak s. PLoS Med. 2019 Apr 30;16(4):e1002790. doi: 10.1371/journal.pmed.1002790. eCollection 2019 Apr. PLoS Med. 2019. PMID: 31039172 Free PMC article. Clinical Trial.
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
Wilkie M, Satti I, Minhinnick A, Harris S, Riste M, Ramon RL, Sheehan S, Thomas ZM, Wright D, Stockdale L, Hamidi A, O'Shea MK, Dwivedi K, Behrens HM, Davenne T, Morton J, Vermaak S, Lawrie A, Moss P, McShane H. Wilkie M, et al. Among authors: vermaak s. Vaccine. 2020 Jan 22;38(4):779-789. doi: 10.1016/j.vaccine.2019.10.102. Epub 2019 Nov 15. Vaccine. 2020. PMID: 31735500 Free PMC article. Clinical Trial.
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
Sheehan S, Harris SA, Satti I, Hokey DA, Dheenadhayalan V, Stockdale L, Manjaly Thomas ZR, Minhinnick A, Wilkie M, Vermaak S, Meyer J, O'Shea MK, Pau MG, Versteege I, Douoguih M, Hendriks J, Sadoff J, Landry B, Moss P, McShane H. Sheehan S, et al. Among authors: vermaak s. PLoS One. 2015 Nov 3;10(11):e0141687. doi: 10.1371/journal.pone.0141687. eCollection 2015. PLoS One. 2015. PMID: 26529238 Free PMC article. Clinical Trial.
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
Minhinnick A, Satti I, Harris S, Wilkie M, Sheehan S, Stockdale L, Manjaly Thomas ZR, Lopez-Ramon R, Poulton I, Lawrie A, Vermaak S, Le Vert A, Del Campo J, Hill F, Moss P, McShane H. Minhinnick A, et al. Among authors: vermaak s. Vaccine. 2016 Mar 8;34(11):1412-21. doi: 10.1016/j.vaccine.2016.01.062. Epub 2016 Feb 5. Vaccine. 2016. PMID: 26854906 Free PMC article. Clinical Trial.
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
Wajja A, Kizito D, Nassanga B, Nalwoga A, Kabagenyi J, Kimuda S, Galiwango R, Mutonyi G, Vermaak S, Satti I, Verweij J, Tukahebwa E, Cose S, Levin J, Kaleebu P, Elliott AM, McShane H. Wajja A, et al. Among authors: vermaak s. PLoS Negl Trop Dis. 2017 May 4;11(5):e0005440. doi: 10.1371/journal.pntd.0005440. eCollection 2017 May. PLoS Negl Trop Dis. 2017. PMID: 28472067 Free PMC article. Clinical Trial.
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.
Wajja A, Namutebi M, Apule B, Oduru G, Kiwanuka S, Akello M, Nassanga B, Kabagenyi J, Mpiima J, Vermaak S, Lawrie A, Satti I, Verweij J, Cose S, Levin J, Kaleebu P, Tukahebwa E, McShane H, Elliott AM. Wajja A, et al. Among authors: vermaak s. Wellcome Open Res. 2018 Sep 19;3:121. doi: 10.12688/wellcomeopenres.14736.1. eCollection 2018. Wellcome Open Res. 2018. PMID: 30687792 Free PMC article.
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
Tameris M, Geldenhuys H, Luabeya AK, Smit E, Hughes JE, Vermaak S, Hanekom WA, Hatherill M, Mahomed H, McShane H, Scriba TJ. Tameris M, et al. Among authors: vermaak s. PLoS One. 2014 Feb 3;9(2):e87340. doi: 10.1371/journal.pone.0087340. eCollection 2014. PLoS One. 2014. PMID: 24498312 Free PMC article.
VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy.
Fletcher HA, Chatterjee M, Cooper A, Hussell T, Kaye PM, Prior J, Reljic R, Vermaak S, Vordermeier M, Williams A, McShane H. Fletcher HA, et al. Among authors: vermaak s. F1000Res. 2018 Apr 23;7:485. doi: 10.12688/f1000research.14386.1. eCollection 2018. F1000Res. 2018. PMID: 29904595 Free PMC article.
17 results